

Site of Care

Promoting convenient, cost-effective, and accessible care for members receiving infusion drug therapy.

Value for members and employers

Site of Care is an Excellus BlueCross BlueShield program that provides cost savings by transitioning members from receiving their treatment at a hospital based infusion center to having it administered in a lower-cost facility or in the member's home.

If a member is receiving an intravenous (IV) formulation of a drug that has a self-injectable formulation which costs less, a pharmacist will call the member to discuss the self-administered option and we'll also talk with the provider to send in the new prescription*.

Ongoing monitoring and support



Plan Review	Our clinical team reviews the medication and treatment plan. If our team believes transition to infusion at home or at a lower-cost facility is appropriate, we will reach out to the member to discuss making that change.
Team Collaboration	For members transitioning to an alternate Site of Care, our team will collaborate with the physician, member, and home infusion agency for the plan and schedule that is most convenient for the member.
Assistance	Our team will also connect members to a Patient Assistance Program for help with out-of-pocket costs and manufacturer discounts, if available.
Plan Monitoring	Our team will continually monitor for members receiving drugs at high-cost facilities and identify new opportunities based on member claims analytics.
Support & Counseling	Support and counseling are available to members throughout the course of treatment. Our team reviews medications, treatments and discusses new therapies and biosimilar drugs that are available to members.
Member Convenience	Our team collaborates with the physician and home infusion agencies to ensure medication is administered in each home location.

* Only applicable to employers that have Excellus BlueCross BlueShield as their pharmacy benefit.



No upfront costs for employers, significant savings

- Our Site of Care program runs on a shared savings model for self-funded employers including Minimum Premium and Article 47.
- Fully insured employers will be enrolled in required Site of Care redirection. This means that if there is an opportunity for a member to use home infusion or a lower-cost facility, that member will be required to change their Site of Care.
- For each transition (from a high-cost facility to a lower-cost infusion site or home, or switch to a lower-cost alternative), the employer will receive 70% of the savings. Excellus BlueCross BlueShield will retain 30% of the savings for administrative fees, a maximum of \$50,000 per member, per drug, per year.
- If no members in the group are transitioned to a lower-cost infusion site or home, or transitioned to a lower-cost alternative, the employer will not be charged.

Riley's story

Riley was driving 20 miles to her infusion center every month to receive Tysabri. Since this drug has restrictions on where it can be administered, she thought that she needed to stay at her facility. Our team was able to find a home infusion agency with specially certified nurses to administer this medication in the member's home, eliminating her driving time and reducing her time off work for infusions.

	Per Claim	Per Year **
Cost of On-Site Facility Administration	\$15,016	\$195,208
Cost of at Home Administration	\$7,427	\$96,551
Employer pays 30% of the Savings	\$2,277	\$29,597
Employer keeps 70% of Savings	\$5,312	\$69,060



** Based on 13 infusions per year.


Included for all employers

Site of Care is included as part of the benefit for all employers.

Beginning 1/1/25 on renewal, fully-insured employers will be enrolled in required Site of Care redirection. This means that if there is an opportunity for a member to use home infusion or a lower-cost facility, that member will be required to change their Site of Care.

Self-funded employers (including Minimum Premium and Article 47) are automatically enrolled in voluntary Site of Care redirection, meaning that the member can choose whether they change their Site of Care. Starting 10/1/24 on renewal (1/1/25 on renewal for Minimum Premium and Article 47), self-funded employers will have the option of requiring Site of Care redirection for members in addition to the option of continuing in the current voluntary program.

Medications included in the Site of Care program



Excellus BlueCross BlueShield maintains a growing, comprehensive list of over 130 maintenance injectable or infusion medications that are eligible for transition to a lower-cost facility for our voluntary program.

Our required program includes approximately 90 medications requiring prior authorization on the medical benefit. Medications that are included in our required Site of Care program will be evaluated for medical necessity and location of services upon review to ensure that the place of service requested is the most cost-effective service location for that specific member's treatment.

Examples include medications for: rheumatoid arthritis, psoriasis, Crohn's disease, ulcerative colitis, multiple sclerosis, anemia, osteoporosis, hereditary angioedema, hemophilia conditions, and select chemotherapies.

As part of the program, our team of pharmacists continuously reviews new medications and treatments that may be administered at home. When a new medication is added to the Site of Care program, our team will reach out to members that may benefit and discuss the option for administration at home.



Questions? Your account management team is available to answer any questions you have about the Site of Care Program.

Learn more at
ExcellusForBusiness.com

